Unlikely to cause harm — often a labeling or packaging issue.
CGMP Deviations: finished products manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
| Brand name | LISINOPRIL AND HYDROCHLOROTHIAZIDE |
| Generic name | LISINOPRIL AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, LISINOPRIL |
| Distributed by / for | Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 |
| NDC | 68180-519-01 |
| Full product label | Lisinopril & Hydrochlorothiazide Tables, USP 20mg/12.5mg, packaged in a)100-count bottles and b) 5000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775 India, a) NDC 68180-519-01, b) 68180-519-30 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Nationwide and Puerto Rico |
| Quantity | 59,520 Bottles |
| Recall initiated | 2016-04-04 |
| Report date | 2016-07-06 |
| Recall completed | 2017-06-01 |
| Recall number | D-1052-2016 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗